Food and medications affect each other's absorption, metabolism, and efficacy. Foods can reduce drug absorption (calcium/iron with bisphosphonates, food with certain antibiotics) or increase it (fat-soluble drug with dietary fat). Medications alter nutrient absorption (proton-pump inhibitors reduce B12 and calcium absorption; antibiotics suppress gut microbiota vitamin K synthesis) or metabolism (phenytoin increases folate catabolism). Nutrient supplements (vitamin K, herbal) can interact with anticoagulants and immunosuppressants. Pharmacokinetic and pharmacodynamic interactions determine clinical significance.
Create food-medication interaction tables for commonly used drugs (warfarin, statins, antibiotics, antacids); predict outcomes of specific food-drug combinations.
From your study of nutrient digestion and absorption, you know that nutrients compete for transporters, require specific pH environments, and can be bound by other compounds in the gut — factors like phytate and oxalate reduce mineral absorption by chelation. Drug absorption operates through the same physical and chemical machinery. The gut lumen, the enterocyte surface, and the hepatic first-pass metabolism system do not distinguish between a nutrient molecule and a drug molecule: both are subject to the same transporters, metabolizing enzymes, and pH-dependent ionization that determine how much of a dose reaches the bloodstream.
Pharmacokinetic interactions occur when food alters a drug's absorption, distribution, metabolism, or excretion (ADME). Absorption interactions are the most common. Calcium, iron, and magnesium are strong chelators: they bind to tetracycline antibiotics, fluoroquinolones, and bisphosphonates in the gut, forming insoluble complexes that are never absorbed. This is why these drugs must be taken on an empty stomach, 30–60 minutes before any food or supplement. The reverse occurs with fat-soluble drugs: griseofulvin (an antifungal), fat-soluble vitamins, and some HIV antiretrovirals have markedly improved absorption when taken with a fatty meal, because dietary fat stimulates bile release, which emulsifies the drug and creates the micellar environment needed for absorption — the same mechanism you learned for fat-soluble vitamins. Metabolism interactions are equally important: grapefruit juice contains furanocoumarins that irreversibly inhibit CYP3A4, an intestinal enzyme responsible for first-pass metabolism of many drugs (statins, calcium channel blockers, immunosuppressants). One glass of grapefruit juice can raise blood levels of a CYP3A4 substrate two- to five-fold, turning a therapeutic dose into a toxic one.
Pharmacodynamic interactions occur when food and drug affect the same physiological target. The most clinically important example is warfarin and vitamin K. Warfarin works by blocking the vitamin K-dependent carboxylation of clotting factors II, VII, IX, and X. Dietary vitamin K from leafy greens provides substrate that competes with warfarin's mechanism, reducing anticoagulant effect. The clinical guidance is not to eliminate vitamin K but to keep it *consistent* — a stable intake allows a stable warfarin dose. Sudden increases (a week of daily spinach salads) or decreases (illness that stops eating) destabilize INR. This is an example where the interaction is predictable and manageable, not a reason to avoid the food entirely.
Drugs also deplete nutrients through effects on absorption or metabolism. Proton pump inhibitors (omeprazole, lansoprazole) suppress gastric acid, which is required for pepsin activation and for releasing protein-bound vitamin B12. Long-term PPI use is associated with B12 deficiency and impaired calcium absorption (calcium carbonate requires acid to dissolve, though calcium citrate does not). Broad-spectrum antibiotics suppress the colonic microbiome that synthesizes vitamin K2; short courses rarely cause clinical deficiency, but patients already on warfarin may see INR rise. Methotrexate and phenytoin both impair folate metabolism, and oral contraceptives can deplete B6 and B12 over time. Recognizing these drug-nutrient depletion patterns is a clinical skill: a patient on long-term PPIs with fatigue and macrocytic anemia warrants B12 assessment, not just investigation of the anemia in isolation.
No topics depend on this one yet.